Pallone Unsure Whether Rare Disease PRV Program Should Be Permanent

By Kelly Lienhard / August 3, 2020 at 4:29 PM
House Energy & Commerce Committee Chair Frank Pallone (D-NJ) is concerned about efforts to make permanent FDA’s rare pediatric disease priority review voucher (PRV) program. Pallone recently asserted that permanently renewing the program would strain FDA’s resources, coming as a bipartisan group of House lawmakers, including several key E&C members, push for legislation that would permanently reauthorize the program. During a recent E&C health subcommittee hearing, Pallone noted that it seems likely the program will continue in some form, though...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.